357401-16-2

Upstream product

• 4291-69-4 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 
• 357401-10-6 12,13-dihydro-2,10-dibenzyloxy-13-(β-D-2,3,4,6-tetra-O-benzylglucopyranosyl)-5H-indolo[2,3-a]carbazole-5,6-dicarboxylic acid anhydride 
• 174402-48-3 12,13-dihydro-2,10-dibenzyloxy-13-(β-D-2,3,4,6-tetra-O-benzylglucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-6-methyl-5,7(6H)-dione 

Relevant academic research and scientific papers

PROCESS FOR PRODUCING INDOLOPYRROLOCARBAZOLE DERIVATIVE

The present invention relates to an industrially preferable process for producing an indolopyrrolocarbazole derivative represented by the formula (I): or a pharmaceutically acceptable salt thereof, which is useful as an anti-cancer agent. The above proce

Practical synthesis of a potent indolocarbazole-based, DNA topoisomerase inhibitor

DNA topoisomerase I inhibitors are currently under investigation as cancer chemotherapy agents of which indolocarbazole glycoside (1) has been identified as a promising candidate. A practical, scalable synthesis of 1 that limits the isolation of cytotoxic compounds to only that of the final product is described. The convergent process features a novel phase transfer-promoted glycosylation of aglycone core (4); subsequent hydrolysis provides anhydride (8). The hydrazine fragment (3), which is coupled with 8, is synthesized via a modification of existing procedures. The coupled product (2) is subsequently hydrogenated to provide 1 in excellent purity via direct crystallization (>99.3 A%).